336 related articles for article (PubMed ID: 18765093)
21. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
22. Aldosterone and cardiovascular disease.
Gaddam KK; Pimenta E; Husain S; Calhoun DA
Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
[TBL] [Abstract][Full Text] [Related]
23. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Young MJ; Funder JW
J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
[TBL] [Abstract][Full Text] [Related]
24. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
25. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
López-Andrés N; Martin-Fernandez B; Rossignol P; Zannad F; Lahera V; Fortuno MA; Cachofeiro V; Díez J
Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2372-82. PubMed ID: 21926338
[TBL] [Abstract][Full Text] [Related]
26. Syndromes that Mimic an Excess of Mineralocorticoids.
Sabbadin C; Armanini D
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):231-5. PubMed ID: 27251484
[TBL] [Abstract][Full Text] [Related]
27. A case of monozygotic twins with primary aldosteronism: a case report.
Yoshida T; Uchiwa Y; Sugimachi K; Naruse M
J Hum Hypertens; 2017 Jun; 31(6):422-423. PubMed ID: 28150818
[No Abstract] [Full Text] [Related]
28. Aldosterone as a Mediator of Cardiovascular Damage.
Buffolo F; Tetti M; Mulatero P; Monticone S
Hypertension; 2022 Sep; 79(9):1899-1911. PubMed ID: 35766038
[TBL] [Abstract][Full Text] [Related]
29. Sleep apnea, aldosterone, and resistant hypertension.
Pimenta E; Calhoun DA; Oparil S
Prog Cardiovasc Dis; 2009; 51(5):371-80. PubMed ID: 19249443
[TBL] [Abstract][Full Text] [Related]
30. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
31. Hypertension and the expanding role of aldosterone.
Mackenzie SM; Connell J
Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
[TBL] [Abstract][Full Text] [Related]
32. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone: a risk factor for vascular disease.
Fritsch Neves M; Schiffrin EL
Curr Hypertens Rep; 2003 Feb; 5(1):59-65. PubMed ID: 12530937
[TBL] [Abstract][Full Text] [Related]
34. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
35. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
Funder JW
Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
[TBL] [Abstract][Full Text] [Related]
36. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Funder JW
Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
[TBL] [Abstract][Full Text] [Related]
37. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
Nishiyama A; Hasegawa K; Diah S; Hitomi H
J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
[TBL] [Abstract][Full Text] [Related]
38. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Azibani F; Benard L; Schlossarek S; Merval R; Tournoux F; Fazal L; Polidano E; Launay JM; Carrier L; Chatziantoniou C; Samuel JL; Delcayre C
Hypertension; 2012 Jun; 59(6):1179-87. PubMed ID: 22547442
[TBL] [Abstract][Full Text] [Related]
39. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
40. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
